eXoZymes Inc(EXOZ) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.2 | Insider Own | 65.52% | Shs Outstand | 9.3M | Perf Week | -7.77% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | -0.05% | Shs Float | 3.2M | Perf Month | -36.67% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | - | Inst Own | 1.26% | Short Float | 0.55% | Perf Quarter | -13.64% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 2.28% | Short Ratio | 2.14 | Perf Half Y | -63.2% |
| Sales | 0.00B | P/B | 9.65 | EPS next 5Y | - | ROA | -115.42% | Short Interest | 0.02M | Perf YTD | -65.14% |
| Book/sh | 0.39 | P/C | 6.24 | EPS past 3/5Y | -110.59% -74.96% | ROE | -187.16% | 52W High | -79.35% ($18.40) | Perf Year | -69.27% |
| Cash/sh | 0.61 | P/FCF | - | Sales past 3/5Y | - | ROIC | -231.85% | 52W Low | 2.56% ($3.70) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -21.64% | Gross Margin | - | Volatility(W/M) | 19.91% 12.09% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.6 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.81 | EPS Q/Q | -17.96% | Profit Margin | - | RSI (14) | 24.72 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.81 | Sales Q/Q | - | SMA20 | -19.39% ($4.71) | Beta | 3.27 | Target Price | - |
| Payout | - | Debt/Eq | 0.3 | Earnings | 2026/8/20 | SMA50 | -34.77% ($5.83) | Rel Volume | 2.02 | Prev Close | $3.75 |
| Employees | 32 | LT Debt/Eq | 0.2 | EPS/Sales Surpr. | - | SMA200 | -51.53% ($7.84) | Avg Volume(3M) | 0.01M | Price | $3.8 |
| IPO | 2024/11/13 | Option/Short | No/Yes | Trades | 233 | Volume | 16,652 | Change | 1.33% |
An innovative synthetic biology company that produces high-value natural compounds through cell-free (biosynthesis) manufacturing technology that does not use living cells. The company has built a platform that leverages its proprietary AI-enhanced enzyme technology called "Exozym" to efficiently mass-produce metabolic health nutraceuticals and pharmaceutical raw materials.
Over the past 1 year, on the lower side
79% below its 1-year high.
Traded more than usual. That is 202% of its average volume.
EXOZ has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #441 of 594 in the industry
Based on market cap of $35M.
ACET#439 Adicet Bio Inc $36M PER - 
EDSA#440 Edesa Biotech Inc $36M PER - EXOZ#441 eXoZymes Inc $35M PER - 
LITS#442 Lite Strategy Inc $35M PER - 
CRVO#443 CervoMed Inc $34M PER - 
FAQ
What kind of company is EXOZ?
EXOZ belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EXOZ?
The market cap of EXOZ is approximately $35M, ranking 5,019 within its sector.
What is the 52-week high and low for EXOZ?
EXOZ has recorded a 52-week high of $18.40 and a low of $3.70.
